Free tool
FAERS Monitor: Gralise
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022544 or its brand name (Gralise, Gabapentin). Reports on generic versions are filed under their own applications.
Reports
300,733
Serious
189,916
63% of reports
Hospitalization
87,410
Death reported
29,651
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective23,993
- fatigue21,544
- nausea18,926
- off label use17,906
- pain17,036
- diarrhoea15,598
- headache14,835
- dizziness13,449
- fall12,687
- dyspnoea11,776
- vomiting10,041
- death9,961
- arthralgia9,707
- asthenia9,637
- pain in extremity9,381
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 874 |
| 2005 | 1,392 |
| 2006 | 1,193 |
| 2007 | 1,391 |
| 2008 | 1,882 |
| 2009 | 2,372 |
| 2010 | 3,430 |
| 2011 | 3,989 |
| 2012 | 6,183 |
| 2013 | 7,179 |
| 2014 | 9,856 |
| 2015 | 16,498 |
| 2016 | 21,037 |
| 2017 | 22,746 |
| 2018 | 27,102 |
| 2019 | 29,628 |
| 2020 | 25,935 |
| 2021 | 22,045 |
| 2022 | 20,707 |
| 2023 | 20,248 |
| 2024 | 19,735 |
| 2025 | 20,633 |
| 2026 | 14,677 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,753,426 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fallSignal | 12,687 | 2.7 | 2.7 | 13,614 |
| pain in extremitySignal | 9,381 | 2.3 | 2.2 | 6,522 |
| pain | 17,036 | 2.0 | 1.9 | 8,103 |
| fatigue | 21,544 | 2.0 | 1.9 | 10,259 |
| dizziness | 13,449 | 1.9 | 1.9 | 5,814 |
| asthenia | 9,637 | 1.8 | 1.8 | 3,487 |
| diarrhoea | 15,598 | 1.7 | 1.7 | 4,598 |
| nausea | 18,926 | 1.7 | 1.7 | 5,393 |
| headache | 14,835 | 1.7 | 1.6 | 4,019 |
| arthralgia | 9,707 | 1.6 | 1.6 | 2,463 |
| vomiting | 10,041 | 1.5 | 1.5 | 1,699 |
| dyspnoea | 11,776 | 1.5 | 1.4 | 1,746 |
| off label use | 17,906 | 1.4 | 1.4 | 2,452 |
| drug ineffective | 23,993 | 1.3 | 1.3 | 1,523 |
| death | 9,961 | 0.8 | 0.8 | 477 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.